Clinical Experience Highlights Exceptional ViaCLYR(TM) Wound Care Results

Presentation at Leading Symposium Shows Rapid Wound Transformation and Strong Antimicrobial Performance

Published on Feb. 22, 2026

Got story updates? Submit your updates here. ›

BioLargo, Inc. announced that clinical experience with ViaCLYR™, an advanced wound irrigation solution from its subsidiary Clyra Medical Technologies, was presented at the Boswick Symposium by Dr. Marcus Gitterle, a respected Key Opinion Leader in wound care. The presentation highlighted outcomes across challenging wound care settings, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds, demonstrating rapid wound transformation, enhanced healing, and strong antimicrobial performance.

Why it matters

The clinical experience shared at the Boswick Symposium underscores the potential of ViaCLYR™ to provide effective antimicrobial support that works with the body's natural healing processes. Having an independent clinician of Dr. Gitterle's stature describe real-world performance that exceeds expectations represents important validation as Clyra Medical Technologies continues its commercial rollout of the product.

The details

Dr. Gitterle, who serves as Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy for the Christus Santa Rosa Hospital System in San Antonio, Texas, and Co-founder and Chief Medical Officer of Wound Centrix LLC, presented clinical results from a multi-site evaluation involving approximately 36 cases across four wound clinics over a four-month period. The presentation detailed several key clinical observations that exceeded initial expectations, including very rapid reduction in wound fluid discharge, noticeable increase in healing activity early in treatment, rapid closure or shortening of wound tunnels, improved wound edge appearance and new skin formation, dramatic wound transformation from chronic, scarred wounds to actively healing wounds, and significant wound shrinkage and reduction in depth, particularly in pressure injuries.

  • The presentation was given on January 28 at the Boswick Symposium, held January 24-30 in Maui, Hawaii.
  • The multi-site clinical evaluation was conducted over a four-month period.

The players

Dr. Marcus Gitterle

Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy for the Christus Santa Rosa Hospital System in San Antonio, Texas, and Co-founder and Chief Medical Officer of Wound Centrix LLC.

Clyra Medical Technologies

A subsidiary of BioLargo, Inc. that focuses on infection control and advanced wound care, developing and commercializing wound care solutions based on its proprietary Copper-Iodine Complex Technology.

BioLargo, Inc.

A cleantech and life sciences innovator and engineering services solution provider that owns Clyra Medical Technologies.

Got photos? Submit your photos here. ›

What they’re saying

“In our multi-site clinical experience involving approximately 36 cases across diverse wound etiologies, ViaCLYR™ demonstrated clinically significant improvements in several wound characteristics, including enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction. Patients with chronic, fibrotic wounds showed rapid transformation to highly proliferative healing wounds-characteristics I found quite unusual given the severity of underlying disease and chronicity. Importantly, we observed no adverse events in our treatment population. The tissue effects we observed are likely related not only to very effective long-duration wound cleansing and biofilm suppression, but also to the beneficial effects of copper on healing processes. Because of the success of this evaluation, we are moving as a group to adoption of CICS as our wound care cleansing modality of choice.”

— Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy, Christus Santa Rosa Hospital System; Co-founder and Chief Medical Officer, Wound Centrix LLC (BioLargo, Inc.)

“The clinical experience shared at the Boswick Symposium underscores what we designed ViaCLYR™ to achieve – effective antimicrobial support that works with the body, not against it. Having an independent clinician of Dr. Gitterle's stature describe real-world performance that exceeds expectations, presented to a highly respected audience of wound care specialists, represents important validation as we continue our commercial rollout.”

— Steve Harrison, Chief Executive Officer of Clyra Medical Technologies (BioLargo, Inc.)

“Hearing clinicians describe transformative clinical outcomes-wounds transitioning from chronic and fibrotic to highly proliferative in remarkably short timeframes-is exactly what drives adoption in wound care. Dr. Gitterle's presentation reinforces the promise of Clyra's technology as we expand access to ViaCLYR™ and support the clinical community with evidence-based solutions.”

— Dennis P. Calvert, Chairman of Clyra Medical Technologies and CEO of BioLargo, Inc. (BioLargo, Inc.)

What’s next

Clyra Medical Technologies continues to support ongoing clinical evaluations and plans additional presentations and publications throughout 2026 as part of its commitment to evidence-based adoption and clinician education.

The takeaway

The exceptional clinical results presented for ViaCLYR™ at the Boswick Symposium demonstrate the potential of Clyra's innovative wound care technology to transform chronic, difficult-to-heal wounds and provide effective antimicrobial support that enhances the body's natural healing processes, reinforcing the promise of this solution as it expands its commercial reach.